Combigan may induce allergies

Article

Combigan (brimonidine 0.2%/timolol 0.5%) can cause allergic symptoms in significant numbers of patients, according to Dr Subash and co-workers from Kingston Hospital, UK.

Combigan (brimonidine 0.2%/timolol 0.5%) can cause allergic symptoms in significant numbers of patients, according to Dr Subash and co-workers from Kingston Hospital, UK.

Thirty-two patients who began Combigan therapy between April 2005 and February 2006 were enrolled to an open-label, prospective, six-month surveillance study. All patients were sent a patient satisfaction questionnaire.

After a mean follow-up of 23.1 weeks, a mean reduction in IOP of 5.5 mmHg was achieved. Greatest IOP lowering was seen in patients who switched from timolol alone and from dorzolamide/timolol combinations. Side effects that resulted in discontinuation of Combigan were tachypnoea (9.4%) and allergic conjunctivitis (34.4%). Patients who did not develop adverse side effects were satisfied with Combigan.

Dr Subash concluded that, although Combigan offers good IOP lowering and is generally safe, a substantial number of patients taking the therapy will develop allergic symptoms.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.